Telemetry Investments L.L.C. bought a new position in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 22,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $113,000. Telemetry Investments L.L.C. owned approximately 0.07% of Paratek Pharmaceuticals at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of Paratek Pharmaceuticals by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 337,110 shares of the specialty pharmaceutical company’s stock valued at $3,271,000 after buying an additional 20,476 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Paratek Pharmaceuticals by 3.2% in the third quarter. Vanguard Group Inc now owns 1,392,044 shares of the specialty pharmaceutical company’s stock valued at $13,504,000 after buying an additional 43,816 shares during the last quarter. Northern Trust Corp raised its holdings in Paratek Pharmaceuticals by 13.1% during the second quarter. Northern Trust Corp now owns 408,846 shares of the specialty pharmaceutical company’s stock worth $4,170,000 after purchasing an additional 47,440 shares in the last quarter. Water Island Capital LLC raised its holdings in Paratek Pharmaceuticals by 53.5% during the third quarter. Water Island Capital LLC now owns 439,726 shares of the specialty pharmaceutical company’s stock worth $4,265,000 after purchasing an additional 153,226 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Paratek Pharmaceuticals by 5.7% during the third quarter. Bank of New York Mellon Corp now owns 136,376 shares of the specialty pharmaceutical company’s stock worth $1,323,000 after purchasing an additional 7,332 shares in the last quarter. Hedge funds and other institutional investors own 73.44% of the company’s stock.

In other Paratek Pharmaceuticals news, Director Thomas John Dietz sold 9,330 shares of the stock in a transaction dated Friday, December 21st. The shares were sold at an average price of $5.01, for a total value of $46,743.30. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $37,575. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last ninety days, insiders sold 16,531 shares of company stock valued at $96,743. 6.20% of the stock is currently owned by corporate insiders.

Shares of Paratek Pharmaceuticals stock opened at $6.40 on Friday. Paratek Pharmaceuticals Inc has a 12-month low of $4.50 and a 12-month high of $14.65. The company has a debt-to-equity ratio of 4.81, a current ratio of 14.41 and a quick ratio of 14.41. The stock has a market capitalization of $207.46 million, a price-to-earnings ratio of -1.79 and a beta of 1.55.

Several research firms recently issued reports on PRTK. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. Canaccord Genuity increased their price target on shares of Paratek Pharmaceuticals from $14.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, January 16th. HC Wainwright reissued a “buy” rating on shares of Paratek Pharmaceuticals in a report on Thursday, February 28th. LADENBURG THALM/SH SH set a $18.00 price target on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, February 28th. Finally, Wedbush reissued an “outperform” rating on shares of Paratek Pharmaceuticals in a report on Wednesday, March 6th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $23.25.

COPYRIGHT VIOLATION WARNING: “Telemetry Investments L.L.C. Buys New Position in Paratek Pharmaceuticals Inc (PRTK)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/telemetry-investments-l-l-c-buys-new-position-in-paratek-pharmaceuticals-inc-prtk/2895597.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Read More: What is the balance sheet?

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.